Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma

NCT00354744 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00354744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
June 30, 2019
Enrollment
109 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma